Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kotaro Nomura
Observed names:
K. NOMURA,
K. Nomura
Institutions:
Juntendo University,
National Cancer Centre Japan,
National Cancer Center Hospital East
Observed institutions:
Juntendo University,
National Cancer Centre Japan,
National Cancer Center Hospital East,
Juntendo University Hospital,
National Cancer Center Exploratory Oncology Research & Clinical Trial Center,
Saitama Medical University
show all 6
ORCID:
0009-0009-1487-6533
Observed ORCID:
0009-0009-1487-6533
OpenAlex ID:
A5032670400
Spatially resolved gene expression profiling of tumor microenvironment reveals key steps of lung adenocarcinoma development
2024
·
Yuma Takano
, Jun Suzuki
, et al.
·
Nature Communications
·
74
Single-cell spatial analysis with Xenium reveals anti-tumour responses of CXCL13 + T and CXCL9+ cells after radiotherapy combined with anti-PD-L1 therapy
2025
·
Shunsuke A. Sakai
, Hidekazu Oyoshi
, et al.
·
British Journal of Cancer
·
21
PDF
Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).
2023
·
Keiju Aokage
, Yoshihisa Shimada
, et al.
·
Journal of Clinical Oncology
·
21
Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
2024
·
Keiju Aokage
, Shohei Koyama
, et al.
·
Clinical Cancer Research
·
16
Prognostic value of the international association for the study of lung cancer grading system and its association with the tumor microenvironment in stage I EGFR-muted lung adenocarcinoma
2024
·
Shoko Kubota
, Tetsuro Taki
, et al.
·
European Journal of Cancer
·
12
Prognostic impact of extranodal extension in patients with pN1–N2 lung adenocarcinoma
2021
·
Kotaro Nomura
, Keiju Aokage
, et al.
·
Journal of Cancer Research and Clinical Oncology
·
10
Impact of central nervous system metastasis after complete resection of lung adenocarcinomas harboring common EGFR mutation – A real-world database study in Japan: The CReGYT-01 EGFR study
2024
·
Shinya Katsumata
, Mototsugu Shimokawa
, et al.
·
European Journal of Cancer
·
9
EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system
2024
·
Kotaro Nomura
, Keiju Aokage
, et al.
·
International Journal of Clinical Oncology
·
8
PDF
Diagnostic Value of Nodal Staging of Lung Cancer With Usual Interstitial Pneumonia Using PET
2022
·
Kotaro Nomura
, Mariko Fukui
, et al.
·
The Annals of Thoracic Surgery
·
8
Spatial intratumor heterogeneity of programmed death-ligand 1 expression predicts poor prognosis in resected non–small cell lung cancer
2024
·
Yusuke Nagasaki
, Tetsuro Taki
, et al.
·
JNCI Journal of the National Cancer Institute
·
7
PDF
Antibodies to peripheral nerve antigens in the sera of Guillain-Barré syndrome
1987
·
T. Negishi
, T. Yamashita
, et al.
·
Journal of Neuroimmunology
·
5
Safety Profile of Neoadjuvant Chemoimmunotherapy With Nivolumab for Patients With Resectable Non-Small Cell Lung Cancer in the Real World (CReGYT-04 Neo-Venus)
2025
·
Kotaro Nomura
, Takuya Watanabe
, et al.
·
The Annals of Thoracic Surgery
·
4
Preoperative Immune-Related Adverse Events in Resectable NSCLC Treated With Neoadjuvant Nivolumab Plus Chemotherapy: A Multicenter Retrospective Analysis
2025
·
Takuya Watanabe
, Kotaro Nomura
, et al.
·
JTO Clinical and Research Reports
·
4
PDF
Prognostic impact of PD ‐ L1 expression in surgically resected EGFR ‐mutant lung adenocarcinoma: A real‐world database study in Japan ( CReGYT ‐01 EGFR study)
2024
·
Kotaro Nomura
, Kazuki Takada
, et al.
·
International Journal of Cancer
·
3
Targeted long-read methylation analysis using hybridization capture suitable for clinical specimens
2025
·
Keisuke Kunigo
, Satoi Nagasawa
, et al.
·
Cell Reports Methods
·
2
Serum Antibodies to Peripheral Nerve Antigens in Guillain‐Barré Syndrome
1988
·
T. NEGISHI
, T. YAMASHITA
, et al.
·
Annals of the New York Academy of Sciences
·
2
Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II–III Lung Adenocarcinoma: A Multicenter CReGYT-03 ALK Study
2026
·
Akira Hamada
, Shinkichi Takamori
, et al.
·
Annals of Surgical Oncology
·
1
Extranodal extension in lung adenocarcinoma: pathological insights and its implication as a histological marker of clinical aggressiveness
2025
·
Shunta Tsuchida
, Tetsuro Taki
, et al.
·
British Journal of Cancer
·
1
Long-term survival outcome after surgical resection of pulmonary neuroendocrine tumors
2025
·
Eisuke Goto
, Keiju Aokage
, et al.
·
Surgery Today
·
1
Adjuvant therapy in pStage IA1–IIA lung adenocarcinoma (pN0): A multicenter study focusing on EGFR mutations and recurrence patterns (CReGYT-01 EGFR study)
2025
·
K. Fujino
, K. Suda
, et al.
·
Lung Cancer
·
1
PDF
Similar Trend in Benefit of Adjuvant Platinum in Lung Cancer Patients Irrespective of Epidermal Growth Factor Receptor Mutation Status
2025
·
Kenichi Suda
, Kosuke Fujino
, et al.
·
European Journal of Cardio-Thoracic Surgery
·
1
Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern
2024
·
Eisuke Goto
, Tetsuro Taki
, et al.
·
Lung Cancer
·
1
Abstract 1211: Biomarker analysis of pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer: EAST ENERGY trial
2024
·
Kotaro Nomura
, Shogo Kumagai
, et al.
·
Cancer Research
·
1
ASO Visual Abstract: Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II–III Lung Adenocarcinoma—A Multicenter CReGYT-03 ALK Study
2026
·
Akira Hamada
, Shinkichi Takamori
, et al.
·
Annals of Surgical Oncology
Lung neuroendocrine cancer induces immunosuppressive macrophages via serotonin to drive resistance to the T cell engager tarlatamab
2026
·
Kotaro Nomura
, Tomoyo Fukami
, et al.
·
Cancer Cell
Show more works
View as search
Works count:
40
Citation count:
213
H-index:
8
I10-index:
6
Year
Topic
Type